Exact Mass: 344.1806

Exact Mass Matches: 344.1806

Found 88 metabolites which its exact mass value is equals to given mass value 344.1806, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Formoterol

3-formylamino-4-Hydroxy-alpha-(N-1-methyl-2-P-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate

C19H24N2O4 (344.1736)


Formoterol is a long-acting (12 hours) beta2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). Inhaled formoterol works like other beta2-agonists, causing bronchodilatation through relaxation of the smooth muscle in the airway so as to treat the exacerbation of asthma. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

3-(2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl)phenol

3-[(4Ar,12aS)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol

C23H24N2O (344.1889)


   
   

alpha,alpha-Diethyl-4,4-bis(2-propynyloxy)stilbene

alpha,alpha-Diethyl-4,4-bis(2-propynyloxy)stilbene

C24H24O2 (344.1776)


   

3-[(4aS,12aR)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol

3-[(4aS,12aR)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol

C23H24N2O (344.1889)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Arformoterol

3-formylamino-4-Hydroxy-alpha-(N-1-methyl-2-P-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate

C19H24N2O4 (344.1736)


Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents COVID info from clinicaltrials, clinicaltrial Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Tamoxifen-ol

2-[4-(1,2-diphenylbut-1-en-1-yl)phenoxy]ethan-1-ol

C24H24O2 (344.1776)


   
   

14beta-Hydroxygelsedine

14beta-Hydroxygelsedine

C19H24N2O4 (344.1736)


   

Dihydrohumantenidine

Dihydrohumantenidine

C19H24N2O4 (344.1736)


   

Hydroxygelsemicine

Hydroxygelsemicine

C19H24N2O4 (344.1736)


   

3,5,5-trimethyl-4-(2-beta-D-glucopyranosyloxy)ethyl-cyclohexa-2-en-1-one

3,5,5-trimethyl-4-(2-beta-D-glucopyranosyloxy)ethyl-cyclohexa-2-en-1-one

C17H28O7 (344.1835)


   

cytospolide N

cytospolide N

C17H28O7 (344.1835)


   
   

formoterol

N-[2-Hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide

C19H24N2O4 (344.1736)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   
   

Granisetron metabolite 1

Granisetron metabolite 1

C18H24N4O3 (344.1848)


   

6,9,12,15,18,21-Tetracosahexaynoic acid

6,9,12,15,18,21-Tetracosahexaynoic acid

C24H24O2 (344.1776)


   

Arformoterol

N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide

C19H24N2O4 (344.1736)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents COVID info from clinicaltrials, clinicaltrial Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

FA 24:12

6,9,12,15,18,21-Tetracosahexaynoic acid

C24H24O2 (344.1776)


   

benoxinate hydrochloride

benoxinate hydrochloride

C17H29ClN2O3 (344.1867)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

1-BOC-3-(4-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

1-BOC-3-(4-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

C17H23F3N2O2 (344.1712)


   

1-BOC-3-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

1-BOC-3-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE

C17H23F3N2O2 (344.1712)


   
   

4-[1-hydroxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]benzene-1,2-diol

4-[1-hydroxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]benzene-1,2-diol

C19H24N2O4 (344.1736)


   

1-BOC-3-([(2-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

1-BOC-3-([(2-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

C17H23F3N2O2 (344.1712)


   

1-BOC-3-([(3-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

1-BOC-3-([(3-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

C17H23F3N2O2 (344.1712)


   

1-BOC-3-([(4-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

1-BOC-3-([(4-TRIFLUOROMETHYL-PHENYL)-AMINO]-METHYL)-PYRROLIDINE

C17H23F3N2O2 (344.1712)


   

tert-butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate

tert-butyl 4-[4-(trifluoromethyl)anilino]piperidine-1-carboxylate

C17H23F3N2O2 (344.1712)


   

tolamolol

tolamolol

C19H24N2O4 (344.1736)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

   

1-{2-[(TERT-BUTOXYCARBONYL)AMINO]ETHYL}-2-METHYL-5-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID

1-{2-[(TERT-BUTOXYCARBONYL)AMINO]ETHYL}-2-METHYL-5-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID

C19H24N2O4 (344.1736)


   

Bis(hexamethyldisilazido)magnesium,Mg(HMDS)2

Bis(hexamethyldisilazido)magnesium,Mg(HMDS)2

C12H36MgN2Si4 (344.1806)


   

2-methyl-4-[(2-propoxybenzoyl)amino]-5-propylpyrazole-3-carboxamide

2-methyl-4-[(2-propoxybenzoyl)amino]-5-propylpyrazole-3-carboxamide

C18H24N4O3 (344.1848)


   

1H-PYRIDO[3,4-B]INDOLE-1-ACETIC ACID, 2-[(1,1-DIMETHYLETHOXY)CARBONYL]-2,3,4,9-TETRAHYDRO-, METHYL ESTER

1H-PYRIDO[3,4-B]INDOLE-1-ACETIC ACID, 2-[(1,1-DIMETHYLETHOXY)CARBONYL]-2,3,4,9-TETRAHYDRO-, METHYL ESTER

C19H24N2O4 (344.1736)


   

SDZ SER 082 fumarate

SDZ SER 082 fumarate

C19H24N2O4 (344.1736)


   

Phenylethanolamine A

Phenylethanolamine A

C19H24N2O4 (344.1736)


   

Sodium 2-[methyl(1-oxododecyl)amino]ethanesulphonate

Sodium 2-[methyl(1-oxododecyl)amino]ethanesulphonate

C15H31NNaO4S+ (344.1871)


   

Mivavotinib

Mivavotinib

C17H21FN6O (344.1761)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

   

(S,S)-Formoterol

N-[2-Hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide

C19H24N2O4 (344.1736)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents COVID info from clinicaltrials, clinicaltrial Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride

4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride

C17H29ClN2O3 (344.1867)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents

   

Monic acid A

Monic acid A

C17H28O7 (344.1835)


   

Camphoric acid bis(trimethylsilyl) ester

Camphoric acid bis(trimethylsilyl) ester

C16H32O4Si2 (344.1839)


   

(S)-laudanine(1+)

(S)-laudanine(1+)

C20H26NO4+ (344.1862)


The (S)-enantiomer of laudanine(1+).

   

(S)-tetrahydropapaverine cation

(S)-tetrahydropapaverine cation

C20H26NO4+ (344.1862)


   
   

(R)-tetrahydropapaverine

(R)-tetrahydropapaverine

C20H26NO4+ (344.1862)


   

(S)-codamine(1+)

(S)-codamine(1+)

C20H26NO4+ (344.1862)


An ammonium ion derivative resulting from the protonation of the amino group of (S)-codamine. The major species at pH 7.3.

   

(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoic acid

(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoic acid

C17H28O7 (344.1835)


   

2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]ethanol

2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]ethanol

C24H24O2 (344.1776)


   

N-cyclohexyl-1-hydroxy-5-nitro-4-spiro[benzimidazole-2,1-cyclohexane]imine

N-cyclohexyl-1-hydroxy-5-nitro-4-spiro[benzimidazole-2,1-cyclohexane]imine

C18H24N4O3 (344.1848)


   

4-(1-azepanyl)-6-hydrazinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine

4-(1-azepanyl)-6-hydrazinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine

C15H20N8O2 (344.1709)


   

1-[1-(4-Butan-2-ylphenyl)ethyl]-3-[(4-fluorophenyl)methyl]thiourea

1-[1-(4-Butan-2-ylphenyl)ethyl]-3-[(4-fluorophenyl)methyl]thiourea

C20H25FN2S (344.1722)


   

1-[(4-Fluorophenyl)methyl]-3-[1-(4-propan-2-ylphenyl)propyl]thiourea

1-[(4-Fluorophenyl)methyl]-3-[1-(4-propan-2-ylphenyl)propyl]thiourea

C20H25FN2S (344.1722)


   

7-Hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-ium

7-Hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2,2-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-ium

C20H26NO4+ (344.1862)


   

Laudanine(1+)

Laudanine(1+)

C20H26NO4+ (344.1862)


An organic cation that is the conjugate acid of laudanine, obtained by protonation of the tertiary amino group.

   

(R)-tembetarine

(R)-tembetarine

C20H26NO4+ (344.1862)


   

[2-(3,4-Dimethylphenyl)-4-quinolinyl]-(1-piperidinyl)methanone

[2-(3,4-Dimethylphenyl)-4-quinolinyl]-(1-piperidinyl)methanone

C23H24N2O (344.1889)


   

1-(tert-butyl)-4-[({[(4-methoxyanilino)carbonyl]oxy}imino)methyl]-3,5-dimethyl-1H-pyrazole

1-(tert-butyl)-4-[({[(4-methoxyanilino)carbonyl]oxy}imino)methyl]-3,5-dimethyl-1H-pyrazole

C18H24N4O3 (344.1848)


   

2-Hydroxy-5-[1-hydroxy-2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzamide

2-Hydroxy-5-[1-hydroxy-2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzamide

C19H24N2O4 (344.1736)


   

6-De(cyclopropylamino)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)abacavir

6-De(cyclopropylamino)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)abacavir

C17H21FN6O (344.1761)


   

2,3-Dihydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide

2,3-Dihydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide

C19H24N2O4 (344.1736)


   

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-trans-6,6A-cis)

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-trans-6,6A-cis)

C19H24N2O4 (344.1736)


   

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-cis-6,6A-trans)

4-Ethoxycarbonyl-6-ethyl-5-methyl-2-(para-tolyl)perhydropyrrolo(3,4-C)pyrrole-1,3-dione (3A,4-cis-6,6A-trans)

C19H24N2O4 (344.1736)


   

3-[(4Ar,12aS)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol

3-[(4Ar,12aS)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol

C23H24N2O (344.1889)


   

(R)-tetrahydropapaverine(1+)

(R)-tetrahydropapaverine(1+)

C20H26NO4 (344.1862)


An organic cation that is the conjugate acid of (R)-tetrahydropapaverine, obtained by protonation of the secondary amino group; major species at pH 7.3.

   

(S)-tembetarine

(S)-tembetarine

C20H26NO4 (344.1862)


A tembetarine obtained by methylation of the tertiary amino function of (R)-reticuline.

   

(R)-laudanine(1+)

(R)-laudanine(1+)

C20H26NO4 (344.1862)


The (R)-enantiomer of laudanine(1+).

   

(2e,4e)-n-{3-[(4e)-5-hydroxy-4-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-3-oxo-2h-pyrrol-2-yl]propyl}hexa-2,4-dienimidic acid

(2e,4e)-n-{3-[(4e)-5-hydroxy-4-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-3-oxo-2h-pyrrol-2-yl]propyl}hexa-2,4-dienimidic acid

C19H24N2O4 (344.1736)


   

1-(dec-9-en-1-yl)-2-hydroxybutane-1,2,4-tricarboxylic acid

1-(dec-9-en-1-yl)-2-hydroxybutane-1,2,4-tricarboxylic acid

C17H28O7 (344.1835)


   

3-[3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

3-[3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

C17H28O7 (344.1835)


   

(2e,4e)-n-(3-{4-[(2e,4e)-hexa-2,4-dienoyl]-5-hydroxy-3-oxo-1,2-dihydropyrrol-2-yl}propyl)hexa-2,4-dienimidic acid

(2e,4e)-n-(3-{4-[(2e,4e)-hexa-2,4-dienoyl]-5-hydroxy-3-oxo-1,2-dihydropyrrol-2-yl}propyl)hexa-2,4-dienimidic acid

C19H24N2O4 (344.1736)


   

5-{6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl}pentyl acetate

5-{6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl}pentyl acetate

C17H28O7 (344.1835)


   

11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

C19H24N2O4 (344.1736)


   

(1r)-8-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium

(1r)-8-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium

[C20H26NO4]+ (344.1862)


   

(1's,3s,4's,6's,7'r,8's,11's)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

(1's,3s,4's,6's,7'r,8's,11's)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

C19H24N2O4 (344.1736)


   

methyl (4ar,5s,11r,11ar)-11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

methyl (4ar,5s,11r,11ar)-11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

C19H24N2O4 (344.1736)


   

(1r,8s,11r,12s)-11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

(1r,8s,11r,12s)-11-amino-3,4-dimethoxy-13-methyl-9-oxa-13-azapentacyclo[9.4.2.1⁸,¹².0¹,¹².0²,⁷]octadeca-2,4,6-trien-10-one

C19H24N2O4 (344.1736)


   

methyl 11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

methyl 11a-hydroxy-5-(hydroxymethyl)-11-methyl-1h,2h,3h,4h,4ah,6h,11h-pyrido[4,3-b]carbazole-5-carboxylate

C19H24N2O4 (344.1736)


   

6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

C19H24N2O4 (344.1736)


   

(2e)-3-[(1s,2s,3s,6r)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

(2e)-3-[(1s,2s,3s,6r)-3-hydroxy-6-isopropyl-2-(methoxycarbonyl)-3-(methoxymethyl)cyclohexyl]-2-(hydroxymethyl)prop-2-enoic acid

C17H28O7 (344.1835)


   

(1'r,3s,4'r,6'r,7's,8'r,11'r)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

(1'r,3s,4'r,6'r,7's,8'r,11'r)-6'-ethyl-11'-hydroxy-1-methoxy-10'-oxa-5'-azaspiro[indole-3,2'-tricyclo[5.3.1.0⁴,⁸]undecan]-2-one

C19H24N2O4 (344.1736)


   

(2r,5s)-5-hydroxy-8-methoxy-8-oxooct-6-en-2-yl (4s,7r)-4,7-dihydroxyoct-2-enoate

(2r,5s)-5-hydroxy-8-methoxy-8-oxooct-6-en-2-yl (4s,7r)-4,7-dihydroxyoct-2-enoate

C17H28O7 (344.1835)


   

6-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium

6-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium

[C20H26NO4]+ (344.1862)


   

(1s)-7-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium

(1s)-7-hydroxy-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium

[C20H26NO4]+ (344.1862)


   

2-[(1s)-1-carboxy-2-methylpropyl]-5-hydroxy-5,7,7-trimethyl-9-oxo-5ah,6h-cyclopenta[g]isoquinolin-2-ium

2-[(1s)-1-carboxy-2-methylpropyl]-5-hydroxy-5,7,7-trimethyl-9-oxo-5ah,6h-cyclopenta[g]isoquinolin-2-ium

[C20H26NO4]+ (344.1862)


   

(2e)-4-[(2s,3s,4s,5r)-3,4-dihydroxy-5-({3-[(2s)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoic acid

(2e)-4-[(2s,3s,4s,5r)-3,4-dihydroxy-5-({3-[(2s)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)oxan-2-yl]-3-methylbut-2-enoic acid

C17H28O7 (344.1835)


   

5-[(1s,2r,5r,6s,7r,8r)-6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl]pentyl acetate

5-[(1s,2r,5r,6s,7r,8r)-6,7-dihydroxy-5-methyl-4-oxo-3,11-dioxabicyclo[6.2.1]undecan-2-yl]pentyl acetate

C17H28O7 (344.1835)